ELTX Elicio Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1601485 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY22.1%
TTM EPS YoY41.8%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-315.3%
ROA-105.3%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets52.4%
Debt / equity0.51x
Current ratio3.43x
Interest coverage-24.46x
Cash quality & payout
Operating cash flow / net income1.03x
Accruals ratio3.6%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | $2.30M | $28.31M |
| Cost of revenue | — | — | — | $0 | $433,000 |
| Gross profit | — | — | — | $2.30M | $27.88M |
| R&D expense | $24.90M | $33.66M | $23.85M | $18.10M | $48.70M |
| SG&A expense | $12.81M | $11.33M | $11.90M | $5.63M | $18.49M |
| Operating income | -$37.71M | -$44.99M | -$35.74M | -$23.73M | -$39.31M |
| Interest expense | $1.13M | $455,000 | $1.06M | $3.60M | — |
| Pretax income | -$39.57M | -$51.90M | — | -$38.80M | -$54.57M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$39.57M | -$51.90M | -$35.20M | -$28.21M | -$54.57M |
| EBITDA | -$37.51M | -$44.66M | -$35.36M | -$23.34M | -$39.22M |
| EPS (basic) | -2.58 | -4.25 | -6.96 | -89.27 | -1.93 |
| EPS (diluted) | -2.58 | -4.25 | -6.96 | -89.27 | -1.93 |
| Weighted avg. shares (diluted) | 15.31M | 12.20M | 5.06M | 315,998 | 28.24M |
| Banking | |||||
| Net interest income | — | — | — | $805,000 | -$1.85M |
| Balance sheet | |||||
| Cash & equivalents | $18.56M | $19.49M | $14.30M | $8.41M | $10.04M |
| Receivables | — | — | — | $0 | — |
| Current assets | $19.31M | $20.69M | $16.35M | $10.72M | $91.25M |
| PP&E, net | $295,000 | $483,000 | $717,000 | $1.15M | $451,000 |
| Total assets | $25.86M | $28.18M | $27.15M | $22.66M | $96.51M |
| Current liabilities | $8.11M | $11.52M | $9.76M | $6.87M | $11.30M |
| Short-term debt | $0 | — | — | — | — |
| Long-term debt | $9.41M | $20.03M | — | — | $0 |
| Total debt | $9.41M | $20.03M | — | — | $0 |
| Total liabilities | $24.23M | $39.49M | $15.77M | $13.75M | $15.01M |
| Shareholders' equity | $1.64M | -$11.31M | $11.37M | -$102.14M | -$74.54M |
| Net debt | -$9.16M | $542,000 | — | — | -$10.04M |
| Shares outstanding | 17.80M | 11.03M | 9.60M | 320,281 | 29.96M |
| Cash flow statement | |||||
| Operating cash flow | -$36.95M | -$37.07M | -$32.69M | -$22.18M | -$52.64M |
| Capital expenditure | $16,000 | $87,000 | $66,000 | $654,000 | $382,000 |
| Free cash flow | -$36.97M | -$37.16M | -$32.76M | -$22.83M | -$53.02M |
| Investing cash flow | -$16,000 | -$84,000 | -$32,000 | -$654,000 | -$382,000 |
| Financing cash flow | $36.70M | $42.32M | $38.61M | $21.20M | $107.17M |
| Depreciation & amortization | $204,000 | $321,000 | $382,000 | $390,000 | $91,000 |
| Stock-based compensation | $2.70M | $1.45M | $1.18M | $579,000 | $12.04M |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.